These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 35863630)
1. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630 [TBL] [Abstract][Full Text] [Related]
2. Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. Godolphin PJ; Fisher DJ; Berry LR; Derde LPG; Diaz JV; Gordon AC; Lorenzi E; Marshall JC; Murthy S; Shankar-Hari M; Sterne JAC; Tierney JF; Vale CL PLoS One; 2022; 17(7):e0270668. PubMed ID: 35802687 [TBL] [Abstract][Full Text] [Related]
3. Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis. Zeraatkar D; Cusano E; Martínez JPD; Qasim A; Mangala S; Kum E; Bartoszko JJ; Devji T; Agoritsas T; Guyatt G; Izcovich A; Khamis AM; Lamontagne F; Rochwerg B; Vandvik P; Brignardello-Petersen R; Siemieniuk RAC BMJ Med; 2022; 1(1):e000036. PubMed ID: 36936570 [TBL] [Abstract][Full Text] [Related]
4. Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis. Albuquerque AM; Tramujas L; Sewanan LR; Williams DR; Brophy JM JAMA Netw Open; 2022 Feb; 5(2):e220548. PubMed ID: 35226077 [TBL] [Abstract][Full Text] [Related]
5. Systemic corticosteroids for the treatment of COVID-19. Wagner C; Griesel M; Mikolajewska A; Mueller A; Nothacker M; Kley K; Metzendorf MI; Fischer AL; Kopp M; Stegemann M; Skoetz N; Fichtner F Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014963. PubMed ID: 34396514 [TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis. Cherian JJ; Eerike M; Bagepally BS; Das S; Panda S Front Pharmacol; 2022; 13():1004308. PubMed ID: 36330085 [No Abstract] [Full Text] [Related]
10. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739 [TBL] [Abstract][Full Text] [Related]
11. Systematic review and meta-analysis of interleulin-6 inhibitors in reducing mortality for hospitalized patients with COVID-19. Alegre-Del-Rey EJ; Fénix-Caballero S; Salmerón-Navas FJ; Gil-Sierra MD; Sierra-Sánchez JF; Díaz-Alersi Rosety RL Farm Hosp; 2022 May; 46(3):166-172. PubMed ID: 36183210 [TBL] [Abstract][Full Text] [Related]
13. Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery. Chung C; Bryant A; Brown PD Cochrane Database Syst Rev; 2018 Jul; 7(7):CD011492. PubMed ID: 29987845 [TBL] [Abstract][Full Text] [Related]
14. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638 [TBL] [Abstract][Full Text] [Related]
15. Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence. Sweeney DA; Lobo SM; Póvoa P; Kalil AC Clin Microbiol Infect; 2024 May; 30(5):611-618. PubMed ID: 38182048 [TBL] [Abstract][Full Text] [Related]
17. Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19. Reid NK; Joyner KR; Lewis-Wolfson TD Ann Pharmacother; 2023 Jul; 57(7):769-775. PubMed ID: 36314277 [TBL] [Abstract][Full Text] [Related]
18. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Karampitsakos T; Papaioannou O; Tsiri P; Katsaras M; Katsimpris A; Kalogeropoulos AP; Malakounidou E; Zarkadi E; Tsirikos G; Georgiopoulou V; Sotiropoulou V; Koulousousa E; Chourpiliadi C; Matsioulas A; Lagadinou M; Sampsonas F; Akinosoglou K; Marangos M; Tzouvelekis A Clin Microbiol Infect; 2023 Mar; 29(3):372-378. PubMed ID: 36273769 [TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
20. Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019. Gao Q; Yin X; Tan B; Wang J; Chen J; Zhao B; Yang Q; Li Z BMC Infect Dis; 2022 Dec; 22(1):929. PubMed ID: 36503381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]